Drug Discovery AI Talk

On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnology, and what this milestone really proves - and doesn't - about AI drug discovery. Produced by Dr. Jake Chen.

In this episode, we examine how AI-native biotechnology companies are reshaping drug discovery through the lens of their intellectual-property portfolios. The evidence suggests that these firms are becoming significantly more productive at generating patentable molecules, yet they have not demonstrated the same advantage in discovering entirely new biological targets. Companies such as Insilico Medicine and Genesis show clear strengths in chemical optimization and development speed, while insitro emphasizes causal biology, human genetics, and disease-relevant data. We explore why AI currently appears better at reducing chemical and search risks than overcoming the biological failures that frequently derail late-stage clinical trials. Ultimately, the most promising model may be an integrated pharmaceutical operating system that combines proprietary experimental data, automated discovery, and clinical development. Produced by Dr. Jake Chen.

In this podcast, we study how integrating agentic AI into autonomous wet labs promises rapid therapeutic innovation, while connecting autonomous models directly to physical lab instruments creates critical security risks. These range from immediate hazards—such as cyber-physical vulnerabilities, sequence-screening evasion, and flawed objective optimization—to systemic risks from unaligned superintelligence and uncontrolled biological synthesis. Mitigating these threats requires a capability-based preparedness framework featuring model-independent hardware interlocks, strict permission boundaries, and mandatory physical controls over automated synthesis. Produced by Dr. Jake Chen.

For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores how molecular-glue drugs such as daraxonrasib overturn that assumption by recruiting cyclophilin A to form a synthetic complex around active RAS, physically blocking its growth signals. From the structural ingenuity behind this molecular trap to emerging clinical promise in pancreatic and other KRAS-driven cancers, the daraxonrasib FDA approval reveals a potential turning point in precision oncology—while examining resistance, patient selection, and what KRAS teaches us about drugging the seemingly impossible. Produced by Dr. Jake Chen.

In this podcast, we show a pivotal shift in 2026 for AI drug discovery toward integrated, AI-native R&D systems that move beyond simple algorithmic tasks to form closed-loop learning environments. In this new phase, the industry focuses on converting physical experiments into causal data to overcome information bottlenecks that mere model scaling cannot solve. Leading experts emphasize that generative abundance is creating a new challenge, making it more difficult to select the right candidate than to design it. Consequently, the bottleneck is migrating from molecular discovery toward clinical development, requiring AI to improve translational success rather than just speed. We suggest that the ultimate competitive advantage now lies in an organization's ability to manufacture proprietary experimental data to train increasingly specialized models. Ultimately, while AI has compressed discovery timelines, the field still awaits independent clinical validation to prove it can reduce pharmaceutical attrition. Produced by Dr. Jake Chen.